Pharma 2020: from vision to decision

The outlook has never seemed more promising - or more ominous

What decisions should you make to successfully launch into 2020? In some respects, pharma’s never had it so good. The tools to develop remarkable new medicines are materialising, demand for its products is escalating and trade is getting easier. Collectively the mature markets generate 59% of the total revenues but they are becoming more difficult places where to prosper. They are demanding better outcomes as a precondition for paying for new medicines. Financial pressures have played a part in hardening healthcare payers’ policies. Crushing demographic and epidemiological factors have compounded these economic woes.

Read more

The market's getting tougher

Tighter regulation, harsher price controls and greater government scrutiny. Tomorrow’s challenge is to develop new medicines that can prevent or cure currently incurable diseases. Today’s challenge is to get to tomorrow – and that’s a tall order in itself.

Read more

There's arguably a bigger hurdle facing pharma

Namely, the rising healhtcare bill. Explore the data, use the Pharma 2020 data explorer to compare key indicators across up to six countries at a time.

Learn more

Major scientific and technological advances, socio-demographic changes, and increasing demand for medicines and trade liberalisation, will revive pharm's fortunes.

But if the industry is to prosper in the future, it must first make sure it has a future. By 2020, the BRIC economies alone will account for 33% of the world’s GDP. Are growth markets a solution to the harsher conditions of the mature ones? Expenditure on medicines is rising far faster in the growth economies than it is elsewhere (see chart below). But serving the growth markets is very difficult, both because of their intrinsic problems and because they vary so much. That means the industry can’t rely on its usual methods for making a profit in mature countries. It has to adopt a totally different strategy – or, rather, different strategies for each market.

Read more

 

 

"It was the best of the times, it was the worst of times..."

Our understanding of breast cancer is being transformed

Pharma's incurring bigger and more frequent financial penalties in the US

Healthcare's consuming a larger share of GDP in rich and poor countries alike

Explore the data

Discover the facts and figures from this report

Our interactive graphic allows you to view and compare data for each country mentioned in the report and to compare any six of them.

Download the report

Read the complete analysis

We look at how pharma companies can reach 2020 in a position to benefit from more favourable conditions thereafter - and the most important decisions senior managers will need to make.

Download now

loading-player

Playback of this video is not currently available


Video: Do pharmaceutical companies have the organisational structure that allows for transformation?

loading-player

Playback of this video is not currently available


Video: 
How can companies address the managerial challenges of the future?

loading-player

Playback of this video is not currently available


Video: 
How can companies address the scientific challenges of the future?

 

loading-player

Playback of this video is not currently available


Video: 
What do pharmaceutical companies need to do differently to continue to be successful?

loading-player

Playback of this video is not currently available


Video: 
What should companies take into account when considering business into the BRIC countries?

Contact us

Mike Swanick
Global Pharmaceuticals and Life Sciences leader
Tel: +1 (267) 330 6060
Email

Douglas Strang
Global Pharmaceuticals and Life Sciences Advisory leader
Tel: +1 (267) 330 3045
Email

Andrew Packman
Tax transparency and total tax contribution leader, PwC UK
Tel: +44 (0)189 552 2104
Email

Peter Kartscher
Global Pharmaceuticals and Life Sciences Assurance Leader
Tel: +972 3 795 4410
Email

Follow us